Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting neutrophil serine proteases in bronchiectasis.

The European respiratory journal·2024
Same author

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

The Lancet. Respiratory medicine·2024
Same author

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.

The European respiratory journal·2024
Same author

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.

American journal of respiratory and critical care medicine·2024
Same author

The 6th World Bronchiectasis and Nontuberculous Mycobacteria Conference Abstract Presentations.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2023
Same author

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.

ERJ open research·2023

Related Experiment Video

Updated: May 22, 2026

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Antimicrobial therapy for bronchiectasis.

Anne E O'Donnell1

  • 1Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Hospital, Washington, DC 20007, USA. odonnela@georgetown.edu

Clinics in Chest Medicine
|May 30, 2012
PubMed
Summary
This summary is machine-generated.

Antibiotics can manage acute bronchiectasis exacerbations and potentially serve as long-term maintenance therapy. However, no specific antibiotics are FDA-approved for bronchiectasis, necessitating individualized treatment plans.

Related Experiment Videos

Last Updated: May 22, 2026

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Bronchiectasis management involves antibiotics for acute exacerbations.
  • Long-term antibiotic strategies may benefit specific patient groups.
  • Current treatment lacks FDA-approved antibiotics for bronchiectasis.

Purpose of the Study:

  • To review the role of antibiotics in bronchiectasis management.
  • To highlight the need for evidence-based, individualized treatment approaches.
  • To discuss the current landscape of antibiotic therapy for bronchiectasis.

Main Methods:

  • Literature review of current guidelines and clinical data.
  • Analysis of antibiotic use in acute and chronic bronchiectasis.
  • Discussion of ongoing clinical trials for inhaled antibiotics.

Main Results:

  • Antibiotics are crucial for acute bronchiectasis exacerbations.
  • No specific antibiotic is FDA-approved for chronic bronchiectasis treatment.
  • Clinical trials are evaluating inhaled antibiotics for long-term use.

Conclusions:

  • Antibiotic therapy is essential for managing bronchiectasis exacerbations.
  • Individualized treatment plans are necessary due to the lack of FDA-approved chronic therapies.
  • Further research and clinical trials are vital for optimizing long-term antibiotic strategies in bronchiectasis.